Although no teratogenic effects were seen in animal testing, the use of Feldene Flash during pregnancy is not recommended. Feldene Flash inhibits prostaglandin synthesis and release through a reversible inhibition of the cyclooxygenase enzyme. This effect, as with other nonsteroidal anti-inflammatory agents has been associated with an increased incidence of dystocia and delayed parturition in pregnant animals when drug administration was continued into late pregnancy. NSAIDs are also known to induce premature closure of the ductus arteriosus in infants.
The presence of piroxicam in breast milk has been determined during initial and long-term dosing conditions (52 days). Piroxicam appeared in breast milk at about 1-3% of the maternal plasma concentration. No accumulation of piroxicam occurred in milk relative to that in plasma during treatment. Feldene Flash is not recommended for use in nursing mothers as the clinical safety has not been established.